Science and Innovations in MedicineScience and Innovations in MedicineНаука и инновации в медицине2500-13882618-754XFSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation2143910.35693/2500-1388-2018-0-2-19-25ArticlesСтатьиResearch ArticleResidual Risk of Cardiovascular Complications in Case of Adequate Lipid-Lowering TherapyОстаточный риск сердечно-сосудистых осложнений при адекватной липидкорригирующей терапииSimerzinVV VСимерзинВ В

PhD, professor of the Faculty Therapy Department, Samara State Medical University.

д.м.н., профессор кафедры факультетской терапии СамГМУ

simerzi@mail.ruFatenkovOV VФатенковО В

PhD, Associate Professor, head of the Faculty Therapy Department, Samara State Medical University.

д.м.н., доцент, заведующий кафедрой факультетской терапии СамГМУ

kdmc@mail.ruGagloevaIV VГаглоеваИ В

PhD, Deputy chief physician of the organizational and methodical work of Samara regional clinical hospital n.a. Eroshevskij TI.

д.м.н., зам. главного врача по организационно-методической работе ГБУЗ «Самарская областная клиническая больница им. Т.И. Ерошевского».

gagloeva@zrenie.ruGalkinaMA AГалкинаМ А

teaching assistant of the Faculty Therapy Department, Samara State Medical University.

ассистент кафедры факультетской терапии СамГМУ.

mkmkmk1977@mail.ruPanishevaYaA AПанишеваЯ А

therapeutist of the Clinics of Faculty Therapy of Samara State Medical University.

врач-терапевт клиники факультетской терапии СамГМУ

jana.panisheva@mail.ruSamara State Medical UniversityСамарский государственный медицинский университетSamara regional clinical hospital n.a. Eroshevskij TIГБУЗ «Самарская областная клиническая больница им. Т.И. Ерошевского»1506201832NO2 (2018)№2 (2018)192510032020Copyright ©; 2018, Simerzin V.V., Fatenkov O.V., Gagloeva I.V., Galkina M.A., Panisheva Y.A.Copyright ©; 2018, Симерзин В.В., Фатенков О.В., Гаглоева И.В., Галкина М.А., Панишева Я.А.2018Simerzin V.V., Fatenkov O.V., Gagloeva I.V., Galkina M.A., Panisheva Y.A.Симерзин В.В., Фатенков О.В., Гаглоева И.В., Галкина М.А., Панишева Я.А.https://creativecommons.org/licenses/by/4.0https://innoscience.ru/2500-1388/article/view/21439

This article is devoted to the problems of residual risk of cardiovascu1ar comp1ications deve1opment for high and very high risk patients under adequate lipid-fowering pharmacotherapy in spite of c^lestera! and tow-density 1ipoproteins target level achievement. Afong with classic risk factors the special atte^ton is given to 1ipoprotein (a) [LP (a)] as the most aggressive factor of cardwvascular system atherosclerotic diseases devetopment and their comp1ications. Great importance is attached to 1ipidopheresis.

В обзорной статье отражены проблемы остаточного (резидуального) риска развития сердечно-сосудистых осложнений (ССО) при проведении адекватной липидкорригирующей фармакотерапии у пациентов высокого и очень высокого риска, несмотря на достижение целевого уровня ХС ЛНП. Наряду с классическими факторами риска особое внимание уделено липопротеину (а) [ЛП (а)] как наиболее агрессивному фактору развития атеросклеротических заболеваний сердечно-сосудистой системы и их осложнений. Большое внимание уделено липидаферезу.

residual risk1ipidopheresis^^vat^n technicsостаточный рисклипидаферезинновационные технологииОбщая заболеваемость взрослого населения России в 2012 году. Статистические материалы. Часть IV. М., 2013Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2(l-2):23-28Multiple Risk Factor Intervention Trial Group. The Multiple Risk Factor Intervention Trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA 1976;235(8): 825-827Keys A, Menotti A, Aravanis C et al. The Seven Countries Study: 2,289 deaths in 15 years. Prev Med. 1984;13:141-154The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice. 2016 Guidelines on Cardiovascular disease prevention in clinical practice. Eur Heart J. doi:10.1093/eurheartj/ehw106Cholesterol Treatment Trialists (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-590Cholesterol Treatment Trialists (CTT) Collaborators. Fulcher J, O’Connel R, Voysey M. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-1405Ference BA, Majeed F, Penumetcha R et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015 Apr 21;65(15):1552-61. doi: 10.1016/j.jacc.2015.02.020Зубарева М.Ю., Сусеков А.В. Программа снижения остаточного (резидуального) сосудистого риска: проект R3i (the Residual Risk Reduction Initiative). Часть I. Факторы остаточного риска. Кардиология. 2010;50(8):76- 83Anping Cai, Liwen Li, Zhang Y. Lipoprotein (a): a promising marker for residual cardiovascular risk assessment. Dis Markers. 2013;35(5):551-559Goettsch WG, Yin DD, Alemao E et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Current Medical Research and Opinion, 2014;20(7):1025-1033Riesen WF, Darioli R, Noll G. Lipid-lowering therapy: strategies for improving Compliance. Curr Med Res Opin 2004;20(2): 165-173Bauwerns M, Schneider MP, Nanchen D. Adherence to statins: updates and practical proposals. Rev Med Suisse. 2016;12(508):445-448Stulc T, Ceska R, Gotto A. Jr. Statin Intolerance: the Clinician’s Perspective. Curr Atheroscler Rep 2015;17(12):69. doi: 10.1007/s11883-015-0552-3Stroes ES, Thompson PD, Corsini A et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;(36):1012 -1022. doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18Banach M, Rizzo M, Toth PP et al. Statin intolerance - an attempt at a unified definition. Position paper from an International. Lipid Expert Panel. Arch MedSci. 2015;11(1):1-23Pedro-Botet J, Schaefer EJ, Bakker Arkema RG. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001;158:183-193Sniderman A, Thanassoulis G, Couture P et al. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering. Journal of Clinical Lipidology. 2012;6(4):303-309Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057-1066Awan Z, Seidah NG, MacFadyen JG et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem. 2012;58(1):183-9. doi: 10.1373/c1inchem.2011.172932Bauwerns M, Schneider MP, Nanchen D. Adherence to statins: updates and practical proposals. Rev Med Suisse. 2016;12(508):445-448Albers JJ, Slee A, O'Brien KD. Relatiohship ofApolipoproteins A-l and B, and Lipoprotein (a) to cardio-vascular outcomes: the AIM-HIGH trial. J Am Coll Cardiol. 2013;62 (17):1575- 1579Anping Cai, Liwen Li, Zhang Y. Lipoprotein (a): a promising marker for residual cardiovascular risk assessment. Dis Markers. 2013;35(5):551 - 559Khera AV, Everett BM, Caulfield MP et al. Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129(6):635-642Koschinsky M, Marcovina SM. Lipoprotin(a). In: C. Ballantyne, ed. Clinical lipidology: a companion to Braunwald's heart disease. Philadelphia: Saunders Elsevier, 2009:130-143Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60(8):716-721Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации Комитета экспертов Всероссийского научного общества кардиологов. М.: Медицина, 2004Murase T, Okubo M, Amemiya-Kudo M. Impact of markedly elevated serum lipoprotein (a) levels on the risk of coronary heart disease. Metabolism. 2007;56(9):1187-1191Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990;10(2):240-245Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report on the National Heart, Lung, and Blood Institute Workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clinical Chemistry. 2003;49(11):1785-1796Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisens e inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57(3):340-351Ezhov MV, Safarova MS, Afanasieva OI et al. Lipoprotein (a) level and apolipoprotein (a) phenotype as predictors of longterm cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis. 2014;235(2):477-482Герасимов A.M., Черкавская О.В., Масленников М.А., Кочетов А. Клеточные механизмы, клинические и морфологические факторы риска развития рестеноза. Вестн. рентгенол. радиол. 2011;(4):58-65Morita Y, Himeno H, Yakuwa H, Usui T. Serum lipoprotein (a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a). Circ J. 2006;70(2):156-162Ежов M.B., Сафарова M.C., Мальчин Ю.Г. и др. Связь высокого уровня липопротеина (а) с проходимостью коронарных артерий в течение первого года после чрескожных коронарных вмешательств. Клиницист 2011;1:18-24.Ежов MВ., Сафарова M.С, Афанасьева О.И. и др. Липопротеин(а) как предиктор неблагоприятного прогноза в отдаленные сроки после операции коронарного шунтирования. Кардиология. 2011;51(1): 18-22Jansen AC, van Aalst-Cohen ES, Tanck MW et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004 Dec;256(6):482-90. doi: 10.1111/j.1365-2796.2004.01405.xChapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126(3):314- 345HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279- 1291Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35(8):1082-1098Aronow WS. PCSK9 Inhibitors. Cardiovasc Pharm Open Access. 2015;(4):4Khan TZ, Pottle A, Pennell DJ, Barbir MS. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein (a) in ischaemic heart disease and refractory angina. Glob CardiolSciPract. 2014;29(1):3 -12Bosch T. Therapeutic apheresis-state of the art in the year 2005. Therapeutic Apheresis and Dialysis. 2005;9(6): 459-468Hovland A, Marcovina S, Hardersen R et al. Three different LDL apheresis columns efficiently and equally reduce lipoprotein (a) concentra-tions in patients with familial hypercholesterolemia and small apolipoprotein (a) particles. J Clin Apher. 2012;46(1):73-76Emmrich U, Hohenstein B, Julius U. Actual situation of lipoprotein apheresis in Saxony in 2013. Atheroscler Suppl. 2015;(18):215-225Thompson GR, Barbir M, Davies D et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208(2):317-321Borberg H. 26 Years of LDL - Apheresis: a review of experience transfusion and apheresis. Science. 2009;41(1): 49-59Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853Jaeger BR, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6:229-239Лопухин ЮМ., Арчаков А.И., Владимиров Ю.А., Коган Э.М. Холестериноз. М.: Медицина, 1983